KCM Investment Advisors LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

KCM Investment Advisors LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 209,961 shares of the company’s stock after selling 11,730 shares during the period. Johnson & Johnson makes up about 1.0% of KCM Investment Advisors LLC’s holdings, making the stock its 28th biggest position. KCM Investment Advisors LLC’s holdings in Johnson & Johnson were worth $30,365,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Resona Asset Management Co. Ltd. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $117,401,000. Islay Capital Management LLC grew its holdings in shares of Johnson & Johnson by 2.6% during the 4th quarter. Islay Capital Management LLC now owns 9,247 shares of the company’s stock valued at $1,337,000 after purchasing an additional 235 shares during the last quarter. AllGen Financial Advisors Inc. lifted its stake in Johnson & Johnson by 1.8% in the fourth quarter. AllGen Financial Advisors Inc. now owns 39,140 shares of the company’s stock worth $5,660,000 after purchasing an additional 696 shares during the last quarter. PAX Financial Group LLC boosted its position in Johnson & Johnson by 2.3% during the fourth quarter. PAX Financial Group LLC now owns 4,492 shares of the company’s stock valued at $650,000 after buying an additional 103 shares during the period. Finally, Conquis Financial LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at about $33,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 4.3 %

JNJ opened at $153.03 on Friday. The firm’s 50 day simple moving average is $159.75 and its two-hundred day simple moving average is $155.91. The company has a market capitalization of $368.77 billion, a PE ratio of 23.01, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.